Avon Lifesciences - Kobo Biotech Share Price

  • 2.28-0.01 (-0.43%)
  • Volume: 14,199
BSE
  • Closed
  • Last Updated On: 08 Sep, 2025, 03:31 PM IST
Loading...
Avon Lifesciences - Kobo Biotech Share Price
  • 2.28-0.01 (-0.43%)
  • Volume: 14,199
Advertisment

Avon Lifesciences share price insights

We don’t have any Insights for this stock currently . We suggest you to explore other sections for more!

Key Metrics

PE Ratio
(x)
-1.08
EPS - TTM
(₹)
-2.11
MCap
(₹ Cr.)
5.43
Sectoral MCap Rank
181
PB Ratio
(x)
0.10
Div Yield
(%)
0.00
Face Value
(₹)
10.00
Beta

Beta

1 Month-0.27
3 Months-0.32
6 Months-0.30
1 Year0.37
3 Years0.57

-0.27
VWAP
(₹)
2.26
52W H/L
(₹)
4.56 / 2.19

Avon Lifesciences Share Price Returns

1 Day-0.43%
1 Week0.89%
1 Month-7.32%
3 Months-15.24%
1 Year-20.28%
3 Years-59.07%
5 Years-64.81%

ET Stock ScreenersTop Score Companies

Check whether Avon Lifesciences belongs to analysts' top-rated companies list?

View Stock Screeners

Avon Lifesciences Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Share Analysis Non Prime User
  • View Stock Score on a 10-point scale
  • See ratings on Earning, Fundamentals, Valuation, Risk & Price
  • Check stock performance
JOIN ET PRIME

Avon Lifesciences Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

Avon Lifesciences Financials

  • Quarterly | AnnualJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Income0.020.000.000.000.02
    Total Income Growth (%)----100.00-
    Total Expenses1.351.261.231.221.24
    Total Expenses Growth (%)7.752.031.28-2.04-30.80
    EBIT-1.33-1.26-1.23-1.22-1.23
    EBIT Growth (%)-----
    Profit after Tax (PAT)-1.33-1.26-1.23-1.22-1.23
    PAT Growth (%)-----
    EBIT Margin (%)0.00---0.00
    Net Profit Margin (%)0.00---0.00
    Basic EPS (₹)-0.56-0.53-0.52-0.51-0.51
    Annual FY 2014 FY 2013 FY 2012
    Total Revenue103.44404.02287.50
    Total Revenue Growth (%)-74.4040.5377.06
    Total Expenses137.71389.15269.83
    Total Expenses Growth (%)-64.6144.2276.90
    Profit after Tax (PAT)-34.8213.9915.12
    PAT Growth (%)-348.82-7.4353.58
    Operating Profit Margin (%)-9.978.2413.31
    Net Profit Margin (%)-33.733.465.26
    Basic EPS (₹)-15.476.224.47
    Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
    Total Revenue0.020.020.020.040.03
    Total Revenue Growth (%)0.00-8.43-53.704.151.58
    Total Expenses4.945.5715.2419.2722.96
    Total Expenses Growth (%)-11.22-63.47-20.89-16.092.92
    Profit after Tax (PAT)-4.93-5.55-15.23-19.23-21.01
    PAT Growth (%)-----
    Operating Profit Margin (%)0.000.000.000.000.00
    Net Profit Margin (%)0.000.000.000.000.00
    Basic EPS (₹)-2.33-2.33-6.39-8.07-8.82

    All figures in Rs Cr, unless mentioned otherwise

    No reported Profit & Loss Statement are available.

  • Annual FY 2014 FY 2013 FY 2012
    Total Assets395.58411.68345.61
    Total Assets Growth (%)-3.9119.1238.25
    Total Liabilities342.50323.78269.95
    Total Liabilities Growth (%)5.7819.9443.14
    Total Equity53.0887.8975.66
    Total Equity Growth (%)-39.6116.1823.22
    Current Ratio (x)1.101.171.26
    Total Debt to Equity (x)3.231.781.34
    Contingent Liabilities0.641.723.07
    Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
    Total Assets71.3975.3379.19230.59236.33
    Total Assets Growth (%)-5.23-4.87-65.66-2.43-1.30
    Total Liabilities204.30203.31201.61337.79324.31
    Total Liabilities Growth (%)0.490.84-40.314.165.84
    Total Equity-132.91-127.98-122.43-107.20-87.97
    Total Equity Growth (%)-----
    Current Ratio (x)0.230.230.230.530.56
    Total Debt to Equity (x)-1.05-1.09-1.15-1.94-2.26
    Contingent Liabilities0.00----

    All figures in Rs Cr, unless mentioned otherwise

  • Annual FY 2014 FY 2013 FY 2012
    Net Cash flow from Operating Activities6.7236.7263.89
    Net Cash used in Investing Activities-4.71-6.99-14.43
    Net Cash flow from Financing Activities-12.85-38.39-26.82
    Net Cash Flow-10.84-8.6622.64
    Closing Cash & Cash Equivalent5.6416.4825.13
    Closing Cash & Cash Equivalent Growth (%)-65.77-34.44-
    Total Debt/ CFO (x)25.514.261.55
    Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
    Net Cash flow from Operating Activities0.200.8793.7613.6714.48
    Net Cash used in Investing Activities--25.09-0.00
    Net Cash flow from Financing Activities-0.15-0.87-120.28-12.24-14.47
    Net Cash Flow0.056,000.00-1.431.430.00
    Closing Cash & Cash Equivalent0.140.130.131.560.13
    Closing Cash & Cash Equivalent Growth (%)8.510.40-91.901,120.30-1.35
    Total Debt/ CFO (x)686.11159.891.5015.2313.74

    All figures in Rs Cr, unless mentioned otherwise

  • Annual FY 2014 FY 2013 FY 2012
    Return on Equity (%)-65.5915.9220.45
    Return on Capital Employed (%)-7.7921.4423.75
    Return on Assets (%)-8.803.394.37
    Interest Coverage Ratio (x)-0.431.811.86
    Asset Turnover Ratio (x)26.0898.0583.11
    Price to Earnings (x)-0.572.284.58
    Price to Book (x)0.370.360.94
    EV/EBITDA (x)-275.003.982.95
    EBITDA Margin (%)-0.6510.7117.09
    Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
    Return on Equity (%)0.000.000.000.000.00
    Return on Capital Employed (%)5.116.1317.9312.2317.62
    Return on Assets (%)-6.90-7.37-19.22-8.34-8.88
    Interest Coverage Ratio (x)0.00-7,406.50-77.78-0.77-0.58
    Asset Turnover Ratio (x)---0.000.00
    Price to Earnings (x)-1.84-0.82-0.86-0.92-0.33
    Price to Book (x)-0.07-0.04-0.11-0.16-0.08
    EV/EBITDA (x)-173.27-97.37-14.66-81.47-79.91
    EBITDA Margin (%)0.000.000.000.000.00

Financial InsightsAvon Lifesciences

      Do you find these insights useful?

      • hate it

      • meh

      • love it

      Avon Lifesciences Technicals

      • Stock doesn't have any Buy/Sell Signals.

      • Price Analysis Data details are not available.

      • Pivot Levels

        R1R2R3PIVOTS1S2S3
        Classic-------

        Average True Range

        5 DAYS14 DAYS28 DAYS
        ATR---

      Avon Lifesciences Peer Comparison

        • 1D
        • 1W
        • 1M
        • 3M
        • 6M
        • 1Y
        • 5Y
        Loading...
      • Ratio Performance

        NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
        Avon Lifesciences -1.080.10-65.59-7.79-8.80-24.66-9.97-33.73-15.471.103.2325.51
        Beryl Drugs54.301.336.0911.963.6215.006.592.731.142.100.431.54
        Unjha Form115.553.5612.9816.918.94-0.873.832.930.912.370.000.00
        Colinz Labs22.521.145.246.854.20-1.5010.137.601.974.170.07-0.44
        Ortin Labs-11.670.4418.8534.775.67-63.9312.105.382.731.110.580.00
        Add More
        Annual Ratios (%)

        Choose from Peers

        • Kamron Labs.
        • Vivanza Biosciences
        • Brawn Biotech
        • Shyama Infosys
        • Advik Labs

        Choose from Stocks

        Peers InsightsAvon Lifesciences

          Do you find these insights useful?

          • hate it

          • meh

          • love it

          Avon Lifesciences Shareholding Pattern

          • Loading...
            Showing Avon Lifesciences Shareholding as on Mar 2024
            CategoryMar 2024Dec 2023
            Promoters44.9544.95
            Pledge0.000.00
            FII0.000.00
            DII0.000.00
            Mutual Funds0.000.00
            Others55.0555.05
          • Showing Shareholding as on Mar 2024
            CategoryNo. of SharesPercentage% Change QoQ
            Promoters1,07,09,10044.95 %0.00
            Pledge00.00 %0.00
            Others1,31,15,90055.05 %0.00

          Avon Lifesciences MF Ownership

          MF Ownership details are not available.

          Avon Lifesciences Corporate Actions

          • Meeting DateAnnounced onPurposeDetails
            Aug 14, 2024Aug 12, 2024Board MeetingQuarterly Results
            May 30, 2024May 23, 2024Board MeetingAudited Results
            Feb 14, 2024Feb 07, 2024Board MeetingQuarterly Results
            Nov 10, 2023Nov 03, 2023Board MeetingQuarterly Results
            Sep 30, 2023May 30, 2023AGM-
          • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
            Final10%1.0Sep 21, 2012May 30, 2012
            Final 10%1.0Jul 22, 2011May 19, 2011
            Final 10%1.0Sep 23, 2010Aug 13, 2010
            Final5%0.0Sep 18, 2002Oct 01, 2002
            Final5%0.5Sep 18, 2002Jul 01, 2002
          • All TypesEx-DateRecord DateAnnounced onDetails
            Rights--Jan 03, 2005Rights ratio: 1 share for every 2 held at a price of Rs 70.0

          About Avon Lifesciences

          Kobo Biotech Ltd., incorporated in the year 1993, is a Small Cap company (having a market cap of Rs 5.46 Crore) operating in Pharmaceuticals sector. Kobo Biotech Ltd. key Products/Revenue Segments include for the year ending 31-Mar-2022. Show More

          • Executives

          • Auditors

          • AK

            Ajit Kamath

            Chairman & Non-Exe.Director
            RK

            Rajendra Kaimal

            Non Executive Director
            AB

            Abhishek Buddhadev

            Independent Director
            SP

            Sunil Pitroda

            Independent Director
            Show More
          • A N Shah & Associates
            N G Jain & Co.

          FAQs about Avon Lifesciences share

          • 1. What's the Avon Lifesciences share price today?
            As on 08 Sep, 2025, 03:31 PM IST Avon Lifesciences share price is down by 0.43% basis the previous closing price of Rs 2.28. Avon Lifesciences share price is Rs 2.28. Return Performance of Avon Lifesciences Shares:
            • 1 Week: Avon Lifesciences share price moved up by 0.89%
            • 3 Month: Avon Lifesciences share price moved down by 15.24%
            • 6 Month: Avon Lifesciences share price moved down by 23.75%
          • 2. What is the PE & PB ratio of Avon Lifesciences ?
            The PE ratio of Avon Lifesciences stands at -2.05, while the PB ratio is -0.04.
          • 3. What is 52 week high/low of Avon Lifesciences share price?
            Avon Lifesciences share price saw a 52 week high of Rs 4.56 and 52 week low of Rs 2.19.
          • 4. What's the market capitalization of Avon Lifesciences ?
            Market Capitalization of Avon Lifesciences stock is Rs 5.43 Cr.
          • 5. What are the returns for Avon Lifesciences share?
            Return Performance of Avon Lifesciences Shares:
            • 1 Week: Avon Lifesciences share price moved up by 0.89%
            • 3 Month: Avon Lifesciences share price moved down by 15.24%
            • 6 Month: Avon Lifesciences share price moved down by 23.75%

          Trending in Markets

          Top Gainers As on 03:59 PM | 08 Sep 2025

          Suven Pharma 1,012.95
          90.06 (9.76%)
          Guj Mineral Dev.539.15
          30.15 (5.93%)
          Bharat Forge1,202.80
          66.10 (5.82%)
          Ashok Leyland137.29
          6.52 (4.99%)
          JP Power20.02
          0.95 (4.99%)

          Top Losers As on 03:57 PM | 08 Sep 2025

          Amber Enterprises7,473.00
          -320.50 (-4.12%)
          EID Parry1,067.30
          -45.50 (-4.09%)
          Trent5,315.50
          -213.00 (-3.86%)
          Godfrey Philips10,657.00
          -416.00 (-3.76%)
          Coromandel Int.2,185.20
          -72.71 (-3.22%)

          DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

          DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

          By using this site, you agree to the Terms of Service and Privacy Policy.

          The Economic Times